Sign up for MarketBeat All Access to gain access to MarketBeat’s full suite of research tools:
Los Angeles Capital Management LLC boosted its holdings in shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD – Get Rating) by 157.8% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 153,308 shares of the biotechnology company’s stock after buying an additional 93,835 shares during the quarter. Los Angeles Capital Management LLC owned approximately 0.10% of Ironwood Pharmaceuticals worth $1,588,000 at the end of the most recent reporting period.
Other institutional investors have also recently bought and sold shares of the company. Gladius Capital Management LP acquired a new position in Ironwood Pharmaceuticals during the second quarter worth approximately $55,000. Banque Cantonale Vaudoise bought a new stake in shares of Ironwood Pharmaceuticals during the second quarter worth approximately $58,000. Captrust Financial Advisors boosted its holdings in shares of Ironwood Pharmaceuticals by 441.7% during the second quarter. Captrust Financial Advisors now owns 6,690 shares of the biotechnology company’s stock worth $77,000 after acquiring an additional 5,455 shares during the period. Lazard Asset Management LLC bought a new stake in shares of Ironwood Pharmaceuticals during the first quarter worth approximately $78,000. Finally, Quantbot Technologies LP bought a new stake in shares of Ironwood Pharmaceuticals during the first quarter worth approximately $109,000.
Ironwood Pharmaceuticals Trading Up 1.2 %
Shares of IRWD stock opened at $11.41 on Monday. The company has a current ratio of 25.78, a quick ratio of 25.78 and a debt-to-equity ratio of 0.67. The stock has a market cap of $1.75 billion, a P/E ratio of 12.01 and a beta of 0.96. The stock has a 50 day simple moving average of $11.88 and a 200 day simple moving average of $11.38. Ironwood Pharmaceuticals, Inc. has a 1 year low of $9.73 and a 1 year high of $12.95.
Ironwood Pharmaceuticals (NASDAQ:IRWD – Get Rating) last issued its quarterly earnings results on Thursday, November 3rd. The biotechnology company reported $0.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.27 by $0.01. The business had revenue of $108.64 million during the quarter, compared to analysts’ expectations of $111.51 million. Ironwood Pharmaceuticals had a return on equity of 30.24% and a net margin of 39.85%. On average, research analysts predict that Ironwood Pharmaceuticals, Inc. will post 1 earnings per share for the current fiscal year.
Analyst Ratings Changes
Separately, StockNews.com cut Ironwood Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, December 17th.
Insider Activity at Ironwood Pharmaceuticals
In related news, CEO Thomas A. Mccourt sold 110,962 shares of the business’s stock in a transaction that occurred on Thursday, January 5th. The stock was sold at an average price of $12.07, for a total value of $1,339,311.34. Following the completion of the sale, the chief executive officer now directly owns 712,440 shares in the company, valued at $8,599,150.80. The sale was disclosed in a filing with the SEC, which is available at this link. 13.10% of the stock is currently owned by corporate insiders.
About Ironwood Pharmaceuticals
(Get Rating)
Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union.
Featured Articles
- Get a free copy of the StockNews.com research report on Ironwood Pharmaceuticals (IRWD)
- CVS Health is Growing into an Integrated Healthcare Organization
- Is C3.ai Stock a ChatGPT Artificial Intelligence Play?
- NVIDIA Outlook Improving: Watchlist Candidate for 2023
- Which Wireless Stock Should You Buy in 2023?
- Is Virgin Galactic Stock Preparing for Lift-Off?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Ironwood Pharmaceuticals, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Ironwood Pharmaceuticals wasn’t on the list.
While Ironwood Pharmaceuticals currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we’ll send you MarketBeat’s list of seven stocks and why their long-term outlooks are very promising.
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by entering your email address below.
Sign up for MarketBeat All Access to gain access to MarketBeat’s full suite of research tools:
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat’s trending stocks report.
Identify stocks that meet your criteria using seven unique stock screeners. See what’s happening in the market right now with MarketBeat’s real-time news feed. Export data to Excel for your own analysis.
As Featured By:
326 E 8th St #105, Sioux Falls, SD 57103
contact@marketbeat.com
(844) 978-6257
© American Consumer News, LLC dba MarketBeat® 2010-2023. All rights reserved.
© 2023 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart’s disclaimer.
